Ivermectin has shown genuine anti-cancer activity in laboratory experiments and animal models across dozens of cancer types, but almost no clinical evidence yet exists to show it works in people with cancer. The gap between what happens in a petri dish and what happens in a patient is enormous in oncology, and ivermectin sits squarely in that gap. A handful of early-phase human trials are now underway, though results so far are limited to safety data and preliminary signals in small groups of patients. For anyone hoping ivermectin is a proven cancer treatment, the honest answer is that it is not, at least not yet. For anyone dismissing the research as baseless, the preclinical science is more substantial than that framing suggests.
What Researchers Have Found in the Lab
Since the early 2010s, studies in cell cultures and animal models have documented ivermectin interfering with cancer in several distinct ways. The drug appears to disrupt signaling pathways that cancer cells rely on for unchecked growth, including ones involved in cell proliferation, survival, and the formation of new blood vessels that tumors need to feed themselves.1Journal of Lab Animal Research. The Anticancer Potential of Ivermectin: Mechanisms of Action and Therapeutic Implications It also triggers programmed cell death in cancer cells through multiple routes. One of these involves disrupting mitochondria, the energy-producing structures inside cells, and generating oxidative stress that cancer cells handle poorly compared to normal cells.2PubMed. Antibiotic ivermectin selectively induces apoptosis in chronic myeloid leukemia through inducing mitochondrial dysfunction and oxidative stress In chronic myeloid leukemia cells, for instance, ivermectin killed the cancer cells while largely sparing normal blood-forming cells, and when researchers added an antioxidant, the killing stopped, confirming that oxidative stress was the mechanism at work.
Beyond directly killing cancer cells, ivermectin has attracted attention for triggering what is called immunogenic cell death. When a cancer cell dies this way, it essentially sends out alarm signals that recruit immune cells to the tumor. In a breast cancer study, ivermectin treatment led to a rush of T cells into tumors that had previously been immunologically “cold,” meaning the immune system had been ignoring them.3PubMed Central. Ivermectin converts cold tumors hot and synergizes with immune checkpoint blockade for treatment of breast cancer The drug also appeared to suppress immune cells that normally protect tumors from attack, shifting the balance in favor of the immune cells that kill cancer. These findings come from mice, not people, but they suggest that ivermectin could theoretically work alongside immunotherapy drugs, a possibility now being tested in at least one human trial.
Cancer Types Where Preclinical Activity Has Been Reported
The range of cancers where ivermectin has shown laboratory activity is unusually broad. Researchers have published results in breast cancer (including triple-negative, one of the hardest-to-treat subtypes), ovarian cancer, cervical cancer, leukemia, glioblastoma, pancreatic cancer, and others.4PubMed Central. Ivermectin as an Alternative Anticancer Agent: A Review of Its Chemical Properties and Therapeutic Potential In glioblastoma, the most aggressive primary brain tumor, ivermectin suppressed tumor growth in two independent mouse models and also inhibited the blood vessel formation tumors depend on.5PubMed. Anthelmintic drug ivermectin inhibits angiogenesis, growth and survival of glioblastoma through inducing mitochondrial dysfunction and oxidative stress The fact that ivermectin can cross the blood-brain barrier at least to some degree has made it of particular interest for brain cancers, where getting drugs into the tumor is a persistent challenge.6PubMed Central. Targeting tumor hypoxia and mitochondrial metabolism with anti-parasitic drugs to improve radiation response in high-grade gliomas
In breast cancer specifically, ivermectin has been shown to preferentially target cancer stem-like cells, a subpopulation thought to drive tumor regrowth and treatment resistance. One study found ivermectin more effectively killed these stem-like cells than the overall tumor cell population, while paclitaxel, a standard chemotherapy drug, showed the opposite pattern, being better at killing bulk tumor cells but less effective against the stem-like fraction.7PubMed. Ivermectin as an inhibitor of cancer stem‑like cells That complementary profile is part of why combination approaches are getting attention.
Reversing Drug Resistance
One of the more intriguing findings involves ivermectin’s ability to help overcome multidrug resistance, a major reason chemotherapy fails. Cancer cells sometimes pump drugs back out through a protein called P-glycoprotein, essentially bailing out the poison before it can work. Research dating back to the 1990s showed that ivermectin could block this pump and was several times more potent at doing so than two other well-known pump inhibitors.8PubMed. Reversal of P-glycoprotein-associated multidrug resistance by ivermectin More recent work found that ivermectin reversed drug resistance in cancer cells not just by directly blocking the pump but by reducing the amount of pump protein the cells produced in the first place.9PubMed Central. Ivermectin reverses the drug resistance in cancer cells through EGFR/ERK/Akt/NF-κB pathway
This matters because drug resistance is a clinical problem with few good solutions. If ivermectin could safely be added to chemotherapy regimens to keep drug-resistant cells from escaping treatment, that would be valuable even if ivermectin had no direct cancer-killing activity of its own. In lab experiments with ovarian cancer cells, the combination of ivermectin with paclitaxel produced stronger anti-cancer effects than paclitaxel alone, including in cell lines that had already developed paclitaxel resistance.10PubMed Central. Ivermectin Strengthens Paclitaxel Effectiveness in High-Grade Serous Carcinoma in 3D Cell Cultures
The Dose Problem
Here is where the story gets complicated. Many of ivermectin’s impressive anti-cancer effects in the lab occur at concentrations well above what is safely achievable in a person’s bloodstream. At the standard anti-parasitic dose, ivermectin blood levels peak in the low nanomolar range, while some cancer cell-killing experiments use concentrations five to fifty times higher. One research group that carefully re-examined ivermectin’s effects on cervical cancer cells found that when they filtered out drug precipitates (tiny clumps that form when the drug does not fully dissolve in culture media), some of the apparent cell-killing effect disappeared. Inhibition of cell growth still occurred, but only at concentrations higher than what is clinically attainable in humans.11PubMed. Ivermectin-induced cell death of cervical cancer cells in vitro a consequence of precipitate formation in culture media
This is not a minor technical caveat. It is the central challenge for ivermectin’s potential in oncology. A drug that kills cancer at concentrations that would also harm the patient is not a cancer treatment. Some researchers argue that ivermectin’s immune-modulating effects may work at lower, safer doses, or that combination strategies could lower the effective dose needed. Others are developing modified versions of the ivermectin molecule and drug delivery systems designed to concentrate the drug at tumor sites while keeping blood levels tolerable.12PubMed Central. Biomimetic platelet-membrane camouflaged ivermectin nanocrystals for tumor homing and breast cancer management In mouse models, nanoparticle delivery systems coated with platelet membranes have been used to get ivermectin to home in on tumors, producing tumor growth inhibition along with immune cell infiltration. Whether these approaches will translate to humans remains unknown.
Where Human Clinical Evidence Stands
As of mid-2025, the clinical evidence for ivermectin in cancer is strikingly thin. A review of gynecologic cancers found only one clinical trial listed on ClinicalTrials.gov investigating ivermectin’s use in cancer patients.13Gynecologic Oncology Reports. Ivermectin and Gynecologic Cancer: What are the data? That trial is a phase I/II study testing ivermectin in combination with balstilimab, an immunotherapy drug, in patients with metastatic triple-negative breast cancer. Early results from the phase I portion reported that the combination was safe and well tolerated, and showed encouraging signs of clinical benefit in a heavily pretreated group of patients.14Journal of Clinical Oncology. A phase I/II study evaluating the safety and efficacy of ivermectin in combination with balstilimab in patients with metastatic triple negative breast cancer But phase I studies are designed primarily to test safety, not to prove a drug works, and the number of patients enrolled so far is small.
The absence of large-scale clinical data is the defining feature of the ivermectin-cancer story right now. Preclinical results across dozens of cancer types, published in reputable journals, have not yet translated into the kind of randomized controlled trials that would tell us whether the drug actually helps patients live longer or better. This is not unusual for drug repurposing research generally. Moving from “it works in a dish” to “it works in a patient” requires years and millions of dollars, and the financial incentive to run large trials for a cheap, generic drug is weak.
Safety at Higher Doses
Ivermectin has a strong safety record at its approved anti-parasitic dose, which is a single weight-based dose or a short course. Billions of doses have been administered worldwide for river blindness and other parasitic diseases. The cancer context, however, would likely require higher or more sustained dosing, and this changes the safety picture considerably.
Post-marketing surveillance and clinical reports have identified rare but serious neurological side effects, including seizures, confusion, and coma, after supratherapeutic exposure. The primary concern is that at high doses, ivermectin can overwhelm the blood-brain barrier’s defense system, particularly a pump protein that normally keeps the drug out of the brain. People whose pump system works less efficiently, whether due to genetics, age, or interactions with other drugs, face higher risk.15PubMed Central. Ivermectin Toxicity in Humans and Animals: Clinical Spectrum, Mechanisms, and Management While neurotoxicity at lower exposures tends to be reversible, high or repeated dosing can lead to structural nerve damage and multi-organ injury.
There is a particular irony here: the same P-glycoprotein pump that ivermectin inhibits to reverse drug resistance in cancer cells is also the pump that protects the brain from ivermectin toxicity. Blocking it in tumors is the goal; blocking it in the brain is the danger. This tension makes dose optimization and targeted delivery especially critical for any future clinical use.16PubMed. Is the antiparasitic drug ivermectin a suitable candidate for the treatment of epilepsy?
Self-Medication and Misinformation Risks
Ivermectin’s public profile surged during the COVID-19 pandemic, and some of that attention has spilled over into cancer. Social media posts and alternative health communities have promoted ivermectin as a cancer cure, sometimes pointing to the genuine preclinical research described above but stripping away all the caveats about dose, species differences, and lack of clinical proof. Observational reports have documented oncology patients self-medicating with veterinary-grade ivermectin, sometimes at dangerous doses, after encountering these claims online.17PubMed. Ivermectin in Cancer Treatment: Should Healthcare Providers Caution or Explore Its Therapeutic Potential?
The risks go beyond simple toxicity. Patients who believe they are treating their cancer with ivermectin may delay or refuse proven therapies. In resource-limited settings, where ivermectin’s low cost is especially appealing, misinformation can divert patients away from available treatments that have actual clinical evidence behind them. The researchers most enthusiastic about ivermectin’s preclinical potential have themselves warned that the absence of clinical studies creates a translational gap that social media enthusiasm cannot bridge.
The Drug Repurposing Landscape
Ivermectin is not unique in having anti-cancer activity discovered long after its original approval. The broader movement to repurpose existing drugs for cancer treatment includes several other anti-parasitic agents, along with drugs developed for diabetes, heart disease, fungal infections, and other conditions.18PubMed Central. Drug Repurposing for Cancer Treatment: A Comprehensive Review The appeal is obvious: these drugs already have established safety profiles, known manufacturing processes, and low costs. Ivermectin, mebendazole, niclosamide, and artesunate are all anti-parasitic drugs that have shown preclinical anti-cancer properties.19PubMed. Antiparasitic agents in oncology: Innovative mechanisms, emerging evidence and clinical potential in cancer treatment
The common barrier for all of them is the same: getting from promising lab data to clinical proof. Generic drugs do not generate the patent-protected revenue that justifies the cost of large randomized trials, so funding typically has to come from academic grants or government agencies rather than pharmaceutical companies. This structural problem, not a conspiracy, explains why promising repurposing candidates like ivermectin sit in preclinical limbo for years.
Chemical Modifications and Next-Generation Compounds
Some researchers are taking a different approach entirely. Rather than trying to make standard ivermectin work as a cancer drug, they are using the ivermectin molecule as a starting scaffold and modifying its chemical structure to boost anti-cancer activity while reducing toxicity. Early results suggest that synthetic ivermectin derivatives can outperform the parent compound against cancer cells in the lab.20European Journal of Medicinal Chemistry Reports. Ivermectin and its synthetic derivatives – A new class of anticancer agents One particularly interesting approach has been to create hybrid molecules by chemically linking ivermectin to other bioactive compounds. An ivermectin-artesunate conjugate, for example, proved several times more active than either parent compound and showed no toxicity to normal reference cells.21ACS Omega. Antiproliferative and Trypanocidal Activity of Ivermectin Bioconjugates
These modified compounds are even further from clinical use than standard ivermectin, since they would need to go through the full drug development pipeline as new chemical entities. But they represent a recognition by the research community that the ivermectin molecule has genuine anti-cancer properties worth building on, even if the molecule itself may not be ideally suited for direct clinical use at its current form and dose.
How Ivermectin Acts on the Immune System Around Tumors
One area where lower, potentially achievable doses might matter is immune modulation. Ivermectin interacts with a family of receptors on the surface of both cancer cells and immune cells that respond to ATP, a molecule that accumulates in the chaotic environment around tumors. By tweaking the sensitivity of these receptors, ivermectin can shift the balance of ATP signaling from a mode that helps cancer cells survive to one that triggers a form of inflammatory cell death.22PubMed Central. Modulation of P2X4/P2X7/Pannexin-1 sensitivity to extracellular ATP via Ivermectin induces a non-apoptotic and inflammatory form of cancer cell death On the immune side, ivermectin appeared to selectively suppress regulatory immune cells that normally put the brakes on anti-tumor immunity, while leaving the killer T cells alone or even boosting their activity.23PubMed Central. Ivermectin converts cold tumors hot and synergizes with immune checkpoint blockade for treatment of breast cancer
This dual action on both sides of the tumor-immune interaction is what makes the combination with checkpoint immunotherapy drugs biologically plausible. Checkpoint drugs work by releasing the brakes on the immune system, but they only help when immune cells are already present in the tumor. If ivermectin can independently recruit immune cells to the tumor while also releasing the brakes via a different mechanism, the two drugs together could theoretically achieve what neither does alone. The ongoing phase I/II trial with balstilimab is testing exactly this hypothesis.
Triple-Negative Breast Cancer as a Test Case
It is not a coincidence that triple-negative breast cancer is the focus of the most advanced clinical work on ivermectin. This subtype lacks the three receptors that targeted therapies for other breast cancers exploit, leaving patients with fewer treatment options. In lab models, ivermectin blocked a protein interaction in triple-negative breast cancer cells that restored their sensitivity to tamoxifen, a hormone therapy that normally does not work against this subtype.24Molecular Cancer Therapeutics. Selective Inhibition of SIN3 Corepressor with Avermectins as a Novel Therapeutic Strategy in Triple-Negative Breast Cancer In a mouse model of triple-negative breast cancer, ivermectin combined with a heat-based therapy produced the strongest tumor damage and programmed cell death of any treatment arm, with no significant weight loss in the animals, suggesting the combination was well tolerated.25PubMed Central. Ivermectin Synergizes with Modulated Electro-hyperthermia and Improves Its Anticancer Effects in a Triple-Negative Breast Cancer Mouse Model
Triple-negative breast cancer also tends to be more immunogenic than other subtypes, which makes it a natural candidate for the immune-modulating approach described above. Patients with this cancer often have few effective options after initial treatment fails, creating both clinical need and ethical justification for testing a repurposed drug with a novel mechanism. If ivermectin can demonstrate meaningful clinical benefit in this tough-to-treat cancer, it would strengthen the case for testing it in other tumor types. If it fails here despite the favorable biology, that would be an important signal too.